Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Light-Based scanner aims to spot inflammation without needles

NCT ID NCT05333978

Diagnosis Sponsor: University of Oklahoma Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new imaging tool called multispectral optoacoustic tomography (MSOT) to see if it could safely detect inflammation in people with graft-versus-host disease, Crohn's disease, or colitis. The device uses light and sound to create images of inflamed areas. The trial was terminated early, but it collected safety data from 29 participants.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MSOT Device
What this could lead to
If successful, this could provide a non-invasive way to detect inflammation in conditions like GVHD, Crohn's, and colitis, potentially reducing the need for biopsies.
What could go wrong
The trial was terminated early with only 29 participants, so results are limited. The device is experimental and not yet proven to be effective for diagnosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

29 people

The number who actually took part.

Started

May 2022

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients documented clinical/pathologic 1) acute or chronic colon or skin GVHD, 2) Crohn's disease, or 3) colitis * Have acceptable hematologic status \[total hemoglobin (tHb) ≥ 7.0 mg/dL\] * Patients ≥ 18 yrs of age * Willing to comply with study procedures and be available for the duration of the study * Patient has ability to understand and the willingness to provide a signed and dated IRB-approved informed consent document. Exclusion Criteria: * Patients with a tattoo over the area of inflammation * Pregnant patients are not eligible for this trial. Eligible patients (if applicable) will be required to document the date of the first day of their last menstrual cycle, and provide a negative pregnancy test if sexually active and of childbearing potential * Patients who are breastfeeding * Any open wound (skin ulcerations or infections) at or near the site of imaging that would preclude MSOT imaging. * Any febrile illness that precludes or delays participation preoperatively

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic graft versus host disease of the skin or gi tract are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic graft versus host disease colitis Crohn disease graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colitis Crohn disease Graft VS host disease

Contacts and locations

Locations

  • University of Oklahoma Health Sciences Center, Stephenson Cancer Center

    Oklahoma City, Oklahoma, 73014, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.